Skip to main content
SpringerLink
Log in

Chemotherapy of Cancer of the Prostate

  • Chapter
Chemotherapy and Urological Malignancy

Part of the book series: Clinical Practice in Urology ((PRACTICE UROLOG))

Abstract

Cancer of the prostate is the second leading cause of cancer deaths among American men (Enstrom and Austin 1977; Third National Cancer Survey 1974). The expected annual incidence is 42000 new cases with 17000 deaths. It has been estimated that 30% of cases are potentially curable when first discovered but this is open to serious question (Klein 1979). Between 1950 and 1970 the reported incidence of prostatic carcinoma rose from 17 to 21 per 100000 population. This rise has been mainly in American nonwhites (Eraster et al. 1978) and has been attributed to improvements in medical care, screening and accuracy of diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alfthan OS, Rusk J (1969) Estracyt in advanced prostatic carcinoma. Ann Chir Gynaecol 58:234–240

    CAS  Google Scholar 

  • Anderson L (1975) International Symposium on Tumours of the Male Genital Tract, Duesseldorf, vol VII pp 24–25

    Google Scholar 

  • Arduino L, Bailar JL, Becker L, et al. (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017

    Google Scholar 

  • Arduino L, Bailer JL, Becker L, et al. (1968) Factors in the prognosis of carcinoma of the prostate: A cooperative study. J Urol 100: 59–65

    Google Scholar 

  • Arduino L, Bailer JL, Becker L, et al. (1978) Carcinoma of the prostatetreatment comparison. J Urol 98: 516–522

    Google Scholar 

  • Bagshaw MA, Ray GR, Pistenma DA, et al. (1975) External beam radiation therapy of primary carcinoma of the prostate. Cancer 36: 723–728

    Article  PubMed  CAS  Google Scholar 

  • Bagshaw MA, Pistenma DA, Ray GR, et al. (1977) Evaluation of extended radiotherapy for prostatic neoplasm: 1976 progress report. Cancer Treat Rep 61: 297–306

    PubMed  CAS  Google Scholar 

  • Barnes R, Hirst A, Rosenquist R (1976) Early carcinoma of the prostate: Comparison of stages A and B. J Urol 115: 404–484

    PubMed  CAS  Google Scholar 

  • Barzell W, Bean MA, Hilaris BS, et al. (1977) Prostatic adenocarcinoma: Relationship of grade and local extent to the patterns of metastases. J Urol 118: 278–282

    PubMed  CAS  Google Scholar 

  • Byar DP (1972a) Survival of patients with incidentally found microscopic cancer of the prostate: Results of a clinical trial of conservation treatment. J Urol 108: 903–913

    Google Scholar 

  • Byar DP (1972b) Treatment of prostatic cancer: Studies by the Veterans Administration Cooperative Urological Research Group (VACURG). Bull NY Acad Med 48: 751–766

    CAS  Google Scholar 

  • Byar DP (1973) The Veterans Administration Cooperative Urologic Research Group studies on cancer of the prostate. Cancer 32: 1126–1130

    Article  PubMed  CAS  Google Scholar 

  • Byar DP (1977) VACURG studies in prostatic carcinoma in urologic pathology. In: Tannenbaum M (ed) The prostate. Lea & Febiger, Philadelphia, p 241

    Google Scholar 

  • Byar DP, Mostofi FK (1972) Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies (examined by the step-section technique). VACURG. Cancer 30: 5–13

    Article  CAS  Google Scholar 

  • Castellino RA, Ray GR, Blank N, et al. (1973) Lymphangiography in prostatic carcinoma: Preliminary observations. JAMA 223: 877–881

    Article  PubMed  CAS  Google Scholar 

  • Catalona WJ, Scott WW (1978) Carcinoma of the prostate: A review, J Urol 119: 1–8

    PubMed  CAS  Google Scholar 

  • Catane R, Kaufman J, Mittelman A, et al. (1977) Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine. J Urol 117: 332

    PubMed  CAS  Google Scholar 

  • Catane R, Kaufman JH, Madajewicz S (1978) Prednimustine therapy for advanced prostatic carcinoma. Br J Urol 50: 29–32

    Article  PubMed  CAS  Google Scholar 

  • Chisholm GD, O’Donoghue EPN, Kennedy CL (1977) The treatment of oestrogen-escaped carcinoma of the prostate with estramustine phosphate. Br J Urol 49: 717–720

    Article  PubMed  CAS  Google Scholar 

  • Chlebowsky RT, Hestorff R, Sadoff L, et al. (1979) Cyclophosphamide versus the combination of adriamycin, 5-fluorouraeil and cyclophosphamide in the treatment of metastatic prostatic cancer. Cancer 42: 2546–2552

    Article  Google Scholar 

  • Chua DT, Veenema RJ, Muggia F, et al. (1970) Acid phosphatase levels in bone marrow: Value in detecting early bone metastasis from carcinoma of the prostate. J Urol 103: 462–466

    PubMed  CAS  Google Scholar 

  • DeWys WD (1975) Comparison of adriamycin (NSC-123127) and 5-fluorouracil (NSC-019893) in advanced prostatic cancer. Cancer Chemother Rep 59: 215–217

    PubMed  CAS  Google Scholar 

  • DeWys WD, Begg CB (1978) Comparison of adriamycin and 5-fluorouracil in advanced prostate cancer. Proc Am Assoc Cancer Res 19: 331

    Google Scholar 

  • DeWys WD, Bauer M, Colsky J, Cooper RA, Creech R, Carbone PP (1977) Comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer-Progress report. Cancer Treat Rep 61: 325–329

    PubMed  CAS  Google Scholar 

  • Eagan R, Hahn R, Myers R (1975) Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-019893) and cyclophosphamide (NSC-026271) in advanced prostatic cancer: A preliminary report. Cancer Chemother Rep 59: 205–207

    Google Scholar 

  • Eagan R, Hahn R, Myers R (1976) Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-019893) and cyclophosphamide (NSC-026271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 60: 115–117

    PubMed  CAS  Google Scholar 

  • Edsmyr F, Esport PL, Johansson V, et al. (1978) Clinical experimental randomized study of 2,6-cisdiphenylhexamethylcyclotetrasiloxane and estramustine-17-phosphate in the treatment of prostatic carcinoma. J Urol 120: 705–707

    PubMed  CAS  Google Scholar 

  • Emmett JL, Greene LF, Papantoniou A (1960) Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies. J Urol 83: 471–484

    PubMed  CAS  Google Scholar 

  • Endostrom JE, Austin DF (1977) Interpreting cancer survival rates. Science 195: 847–857

    Article  Google Scholar 

  • Ernster VL, Selvin S, Winkelstein WJ Jr (1978) Cohort mortality for prostatic cancer among United States nonwhites. Science 200: 1165–1166

    Article  PubMed  CAS  Google Scholar 

  • Flocks RH, O’Donoghue EPN, Milleman LA, et al. (1975) Management of stage C prostatic carcinoma. Urol Clin North Am 2: 163–179

    PubMed  CAS  Google Scholar 

  • Fossa SD, Miller A (1976) Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115: 406–408

    PubMed  CAS  Google Scholar 

  • Fossa SD, Sokolowski J, Theodorsen L (1978) The significance of bone marrow acid phosphatase in patients with prostatic carcinoma. Br J Urol 50: 185–189

    Article  PubMed  CAS  Google Scholar 

  • Gleason DF (1977) Histologic grading clinical staging of prostatic carcinoma in urologic pathology. In: Tannenbaum M (ed) The prostate. Lea & Febiger, Philadelphia, p 17

    Google Scholar 

  • Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58–64

    PubMed  CAS  Google Scholar 

  • Golimbu M, Schinella R, Morales P, et al. (1978) Differences in pathological characteristics and prognosis of clinical A2 prostatic cancer from Al and B disease. J Urol 119: 618–622

    PubMed  CAS  Google Scholar 

  • Greene LF, Simon HB (1955) Occult carcinoma of the prostate: Clinical and therapeutic study of eight-three cases. JAMA 158: 1494–1498

    CAS  Google Scholar 

  • Hanash KA, Utz DC, Cook EN, et al. (1972) Carcinoma of the prostate: A 15-year follow-up. J Urol 107: 450–453

    PubMed  CAS  Google Scholar 

  • Heaney JA, Change HC, Daly JJ, et al. (1977) Prognosis of clinically undiagnosed prostatic carcinoma and the influence of endocrine therapy. J Urol 118: 283–287

    PubMed  CAS  Google Scholar 

  • Hill DR, Crews QE Jr, Walsh PC (1974) Prostate carcinoma: Radiation treatment of the primary and regional lymphatics. Cancer 34: 156–160

    Article  PubMed  CAS  Google Scholar 

  • Houghton AL, Robinson MR, Smith PH (1977) Melphalan in advanced prostatic cancer: A pilot study. Cancer Treat Rep 61: 923–924

    PubMed  CAS  Google Scholar 

  • Housepian JA, Byar DP (1976) VACURG: Carcinoma of the prostate: Correlation between radiologic quantitation of metastases and patient survival. Urology 6: 11–16

    Google Scholar 

  • Ihde D, Bunn P, Cohen M, et al. (1978) Combination chemotherapy in metastatic carcinoma of the prostate: Method of detecting tumor response and progression. Proc AACR/ASCO 19:339

    Google Scholar 

  • Ishihe T, Isui T, Nahira H (1974) Prognosis usefulness of serum acid phosphatase levels in carcinoma of the prostate. J Urol 112: 237–240

    Google Scholar 

  • Izbecki R, Amer M, Al-Sarraf MA (1978) A prospective study of a combination of adriamycin and Cytoxan in the treatment of patients with advanced prostatic cancer. Proc AACR/ASCO 19:312

    Google Scholar 

  • Jewett HJ (1975) The present status of radical prostatectomy for stage A and B prostatic cancer. Urol Clin North Am 2: 105–124

    PubMed  CAS  Google Scholar 

  • Jewett HJ, Eggleston JC, Yawn DH (1972) Radical prostatectomy in the management of carcinoma of the prostate: Probable causes of some therapeutic failures. J Urol 107: 1034–1040

    PubMed  CAS  Google Scholar 

  • Johnson DE, Scott WW, Gibbons RP, et al. (1976) Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology 8: 123–126

    Article  PubMed  CAS  Google Scholar 

  • Jonsson G, Hogberg B (1971) Treatment of advanced prostatic carcinoma with Estracyt. Scand J Urol Nephrol 5: 103–107

    Article  PubMed  CAS  Google Scholar 

  • Kadohama N, Kirdani RY, Murphy GP, et al. (1978) Estramustine phosphate: Metabolic aspects related to its action in prostatic cancer. J Urol 119: 235–239

    CAS  Google Scholar 

  • Kane RD, Stocks LH, Paulson DF (1977) Multiple-drug chemotherapy regimen for patients with hormonally unresponsive carcinoma of the prostate: A preliminary report. J Urol 117:467–471

    PubMed  CAS  Google Scholar 

  • Kennealey G, March J, Welch D, et al. (1978) Treatment of advanced carcinoma of the prostate with estramustine plus 5-FU. Proc AACR/ASCO 19: 394

    Google Scholar 

  • Kent JR, Bishoff AJ, Arduino LJ (1973) Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol 109: 858–860

    PubMed  CAS  Google Scholar 

  • Klein LA (1979) Medical progress: Prostatic carcinoma. N Eng J Med 300: 824–833

    Article  CAS  Google Scholar 

  • Labess M (1952) Occult carcinoma in clinically benign hypertrophy of the prostate: A pathological and clinical study. J Urol 68: 893–896

    PubMed  CAS  Google Scholar 

  • Lerner H, Malloy T (1977) Hydroxyurea in stage D carcinoma of prostate. Urol 1: 35–38

    Article  Google Scholar 

  • Lindberg B (1972) Treatment of rapidly progressing prostatic carcinoma with estracyt. J Urol 108: 303– 306

    PubMed  CAS  Google Scholar 

  • Mackler MA, Liberti JP, Smith MJV, et al. (1972) The effect of orchiectomy and various doses of stilbestrol of plasma testosterone levels in patients with carcinoma of the prostate. Invest Urol 9:423

    PubMed  CAS  Google Scholar 

  • McCullough DL, Leadbetter WF (1972) Radical pelvic surgery for locally extensive carcinoma of the prostate. J Urol 108: 939–943

    PubMed  CAS  Google Scholar 

  • Merrin C (1978a) Preliminary report on combination chemotherapy for advanced prostatic carcinoma. Cancer Treat Rep 61: 313–315

    Google Scholar 

  • Merrin C (1978b) Treatment of advanced carcinoma of the prostate (stage D) with infusion of cis- diamminedichloroplatinum (II NSC 119875): A pilot study. J Urol 119: 522–524

    PubMed  CAS  Google Scholar 

  • Merrin C, Beckley S (1979) The treatment of estrogen-resistant stage D carcinoma of the prostate with cis-diamminedichloroplatinum. Urology 13: 256–272

    Article  Google Scholar 

  • Merrin C, Etra W, Wajsman Z, et al. (1976) Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. J Urol 115: 86–88

    PubMed  CAS  Google Scholar 

  • Mittelman A, Shukla SK, Welvaar TK, et al. (1975) Oral estramustine phosphate in the treatment of advanced stage D carcinoma of the prostate. Cancer Treat Rep 59: 219–223

    CAS  Google Scholar 

  • Mittelman A, Shukla SK, Murphy GP (1976) Extended therapy of stage D carcinoma of the prostate with oral extramustine phosphate. J Urol 115: 409–412

    PubMed  CAS  Google Scholar 

  • Muntzing J, Shukla SK, Chu TM, et al. (1974) Pharmacoclinical study of oral estramustine phosphate (ESTRACYT) in advanced carcinoma of the prostate. Invest Urol 12: 65–68

    PubMed  CAS  Google Scholar 

  • Murphy G, Gibbons R, Johnson D, et al. (1977) A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol 118: 288

    PubMed  CAS  Google Scholar 

  • Nagel R, Kollin CP (1976) Treatment of advanced carcinoma of the prostate with estramustine phosphate. J Urol 115: 406–408

    Google Scholar 

  • Nagel R, Kollin CP (1977) Treatment of advanced carcinoma of the prostate with estramustine phosphate. Br J Urol 49: 73–79

    Article  PubMed  CAS  Google Scholar 

  • Nesbit RM, Plumb RT (1946) Prostatic carcinoma: A follow-up on 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy. Surgery 20: 263–272

    PubMed  CAS  Google Scholar 

  • Nilsson T, Jonsson G (1975) Clinical results with estramustine phosphate: A comparison of intravenous and oral preparations. Cancer Chemother Rep 59: 229–232

    PubMed  CAS  Google Scholar 

  • O’Bryan RM, Baker LH, Gottlieb JE, et al. (1977) Dose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948

    Article  PubMed  Google Scholar 

  • Paulson D, Berry W, Walker A, et al. (1978) Multiagent chemotherapy in advanced prostatic cancer-Measurement of response. AACR/ASCO 19: 325

    Google Scholar 

  • Perloff M, Ohnuma T, Holland JF, et al. (1977) Adriamycin (ADM) and diamminedichloroplatinum (DDP) in advanced prostatic carcinoma (PC). Proc AACR/ASCO C-265: 333

    Google Scholar 

  • Pontes JE, Choe BK, Rose NR, et al. (1978) Bone marrow acid phosphatase in staging of prostatic cancer: How reliable is it? J Urol 119: 772–776

    PubMed  CAS  Google Scholar 

  • Ray GR, Cassady JR, Bagshaw MA (1973) Definitive radiation therapy of carcinoma of the prostate. Radiology 106: 407–418

    PubMed  CAS  Google Scholar 

  • Rubin P (1969) The detection of occult metastatic cancer by radioactive bone scans. JAMA 210: 1079–1080

    Article  PubMed  CAS  Google Scholar 

  • Schaffer DL, Pendergrass HP (1976) Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 121:431–434

    PubMed  CAS  Google Scholar 

  • Schmidt JD, Johnson DE, Scott WW, et al. (1976) Chemotherapy of advanced prostatic cancer: Evaluation of response parameters. Urology 6: 602–610

    Article  Google Scholar 

  • Schmidt JD, Scott WW, Gibbons RP, et al. (1979) Comparison of procarbazine, imidazole carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol 121: 185–189

    PubMed  CAS  Google Scholar 

  • Schroeder FH, Belt E (1975) Carcinoma of the prostate: A study of 213 patients with stage C tumors treated by total perineal prostatectomy. J Urol 114: 257–260

    PubMed  CAS  Google Scholar 

  • Scott W, Johnson DE, Schmidt JE, et al. (1967) Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: Results of First National Randomized Study. J Urol 114: 909–911

    Google Scholar 

  • Scott WW, Gibbons RP, Johnson DE, et al. (1975) Comparison of 5-fluorouracil (NSC-019893) and cyclophosphamide (NSC-026271) in patients with advanced carcinoma of the prostate. Cancer Chemother Rep 59: 195–201

    Google Scholar 

  • Scott WW, Gibbons RP, Johnson DE, et al. (1976) The continued evaluation of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 116: 211–213

    PubMed  CAS  Google Scholar 

  • Shearer RJ, Hendry WF, Sommerville IF, Ferguson JD (1973) Plasma testosterone; an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668–677

    Article  PubMed  CAS  Google Scholar 

  • Slavik M, Carter SK (1970) Single agents in prostatic cancer-A quick review. National Cancer Institute Departmental Memorandum

    Google Scholar 

  • Tejada F, Broder LE, Cohen MJ, et al. (1977a) Treatment of metastatic prostatic cancer with 5-fluorouracil (5-FU) versus l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU). (Abstract) Proc AACR/ASCO C-10: 269

    Google Scholar 

  • Tejada F, Eisenberger MA, Broder LA, et al. (1977b) 5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer. Cancer Treat Rep 61: 1589–1590

    PubMed  CAS  Google Scholar 

  • Third National Cancer Survey (1974) Advanced three-year report (DHEW National Institutes of Health, Bethesda (DHEW publication no. [NIH] 74–637)

    Google Scholar 

  • Van Amburg AL, Presant G, Klahr C (1979) Chemotherapy of advanced prostatic cancer with adriamycin (A), BCNU (B) and cyclophosphamide (C). Proc AACR/ASCO 20: 321, C-126

    Google Scholar 

  • Veterans Administration Cooperative Urological Research Group (1967) Carcinoma of the prostate: Treatment comparisons. J Urol 98: 516–522

    Google Scholar 

  • VonHoff DD, Rozencweig M, Slavik M, et al. (1977) Estramustine phosphate: A specific chemothera-peutic agent. J Urol 117: 464–466

    CAS  Google Scholar 

  • Whitmore WF Jr (1956) Hormone therapy in prostatic cancer. Am J Med 21: 697–713

    Article  PubMed  Google Scholar 

  • Whitmore WF Jr (1963) The rationale and results of ablative surgery for prostatic cancer. Cancer 16: 1119–1132

    Article  PubMed  Google Scholar 

  • Whitmore WF Jr, MacKenzie AR (1959) Experience with various operative procedures for the total excision of prostatic cancer. Cancer 12: 396–405

    Article  PubMed  Google Scholar 

  • Whitmore WF Jr, Hilaris B, Grabstald H, et al. (1974) Implantation of 125I in prostatic cancer. Surg Clin North Am 54: 887–895

    PubMed  Google Scholar 

  • Woodward HQ (1952) Factors leading to elevations in serum acid glycerophosphatase. Cancer 5: 236–241

    Article  PubMed  CAS  Google Scholar 

  • Yam LT (1974) Clinical significance of the human acid phosphatases: A review. Am J Med 56:604–616

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. F. M. Torti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. K. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Oncology, The Albany Medical College, Albany, New York, 12208, USA

    A. S. D. Spiers MB, BS, MD(Melb.), PhD, FRCPE, FRACP, FACP (Professor of Medicine) (Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1982 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Torti, F.M., Carter, S.K. (1982). Chemotherapy of Cancer of the Prostate. In: Spiers, A.S.D. (eds) Chemotherapy and Urological Malignancy. Clinical Practice in Urology. Springer, London. https://doi.org/10.1007/978-1-4471-1332-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1332-4_7

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-1334-8

  • Online ISBN: 978-1-4471-1332-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation